加载中
NASDAQHealthcareMedical - Pharmaceuticals
最新数据
US$5.45
−US$0.134 · -2.40%
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
常规交易时段
US$5.45
−US$0.134 · -2.40%
盘中时间采用ET。市场数据可能有所延迟。
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
日内区间
当前US$5.45
52周区间
当前US$5.45
盘中时间采用ET。市场数据可能有所延迟。
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
日内区间
当前US$5.45
52周区间
当前US$5.45
近期已公布业绩
近期已公布业绩
年度分割调整后的每股现金分配。
US$0.0264
2025年（完整年度）+46.4% 自从 2021
2026年（部分年度）：US$0.036
US$0.018
2,021
US$0.027
2,022
US$0.032
2,023
US$0.034
2,024
US$0.0264
2,025
US$0.036
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年9月8日 | US$0.036Annual | 2026年9月8日 | 2026年9月28日 |
股息 | 2025年9月8日 | US$0.0264Annual | 2025年9月8日 | 2025年9月29日 |
股息 | 2024年9月9日 | US$0.034Annual | 2024年9月9日 | 2024年9月30日 |
股息 | 2023年9月7日 | US$0.032Annual | 2023年9月8日 | 2023年10月2日 |
股息 | 2022年9月9日 | US$0.027Annual | 2022年9月12日 | 2022年10月3日 |
股息 | 2021年9月3日 | US$0.018Annual | 2021年9月7日 | 2021年9月27日 |
除息 2026年9月8日
US$0.036
Annual
2026年9月8日登记 · 支付日 2026年9月28日
除息 2025年9月8日
US$0.0264
Annual
2025年9月8日登记 · 支付日 2025年9月29日
除息 2024年9月9日
US$0.034
Annual
2024年9月9日登记 · 支付日 2024年9月30日
除息 2023年9月7日
US$0.032
Annual
2023年9月8日登记 · 支付日 2023年10月2日
除息 2022年9月9日
US$0.027
Annual
2022年9月12日登记 · 支付日 2022年10月3日
除息 2021年9月3日
US$0.018
Annual
2021年9月7日登记 · 支付日 2021年9月27日
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
